Garry Ph.D. Nolan - 01 Jun 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Reporting relationship: Director
Issuer ticker: AKYA
Reported as of: 01 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2023, 17:36:40 UTC
Prior SEC filing: 27 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Garry Nolan, Ph.D., by Brian McKelligon, as Attorney-in-Fact

Key filing fact

Garry Ph.D. Nolan filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 05 Jun 2023.

Key facts

This page summarizes Garry Ph.D. Nolan's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2023, 17:36.

Change

Previous filing in this sequence was filed on 27 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKYA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +56,322
Change %
Price: $0.000000
Shares after: 56,322
Date: 01 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,322
Exercise price: $5.70
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.